Unge P, Jönsson B, Stålhammar N O
Sandviken Hospital, Sweden.
Pharmacoeconomics. 1995 Nov;8(5):410-27. doi: 10.2165/00019053-199508050-00005.
This study compares the cost effectiveness of Helicobacter pylori eradication and conventional treatment in duodenal ulcer patients treated by a general practitioner. Using a Markov chain approach, Swedish cost data and a study period of 5 years, we conclude that H. pylori eradication with omeprazole and appropriate antibiotics is a cost-effective alternative compared with both maintenance and episodic treatment. Of the patients entering the eradication strategy, most are cured and will have no relapse during a 5-year period. H. pylori eradication results in higher initial costs but, because of a very low risk of recurrence after successful eradication, the expected future costs are reduced. The investment pays off within 1 year when compared with maintenance treatment, and within 3 years when compared with episodic treatment.
本研究比较了全科医生治疗十二指肠溃疡患者时,幽门螺杆菌根除疗法与传统疗法的成本效益。采用马尔可夫链方法、瑞典成本数据以及5年的研究期,我们得出结论:与维持治疗和按需治疗相比,使用奥美拉唑和适当抗生素进行幽门螺杆菌根除是一种具有成本效益的替代方案。在采用根除策略的患者中,大多数得以治愈,且在5年内不会复发。幽门螺杆菌根除疗法导致初始成本较高,但由于成功根除后复发风险极低,预期的未来成本会降低。与维持治疗相比,该投资在1年内就能收回成本;与按需治疗相比,则在3年内收回成本。